Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer

Laboratory Investigation

Volumn 82, Issue 10, 2002, Pages 1419-1426

  Glöckner, Sabine ^a   Buurman, Hilke ^a   Kleeberger, Wolfram ^a   Lehmann, Ulrich ^a   Kreipe, Hans ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; DNA TOPOISOMERASE (ATP HYDROLYSING);

ARTICLE; BREAST CANCER; CLONE; CONTROLLED STUDY; GENE AMPLIFICATION; GENETIC HETEROGENEITY; GENETIC STABILITY; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; ONCOGENE C ERB; ONCOGENE C MYC; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REGULATOR GENE; SOMATIC MUTATION;

BREAST NEOPLASMS; CYCLIN D1; FEMALE; GENE AMPLIFICATION; GENES, MYC; HUMANS; POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2;

EID: 0036798620     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.LAB.0000032371.16521.40     Document Type: Article

References (24)

1. Bieche I and Lidereau R (1995). Genetic alterations in breast cancer. Genes Chromosom Cancer 14:227-251.
2. Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CK, Musgrove EA, and Sutherland RL (1993). Expression and amplification of cyclin genes in human breast cancer. Oncogene 8:2127-2133.
3. Cooke T, Reeves J, Lanigan A, and Stanton P (2001). HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol 12:S23-S28.
4. De Corte V, De Potter C, Vandenberghe D, Van Laerebeke N, Azam M, Roels H, Mareel M, and Vandekerckhove J (1994). A 50 kDa protein present in conditioned medium of COLO-16 cells stimulates cell spreading and motility, and activates tyrosine phosphorylation of Neu/HER-2, in human SK-BR-3 mammary cancer cells. J Cell Sci 107:405-416.
5. Fujii H, Marsh C, Cairns P, Sidransky D, and Gabrielson E (1996). Genetic divergence in the clonal evolution of breast cancer. Cancer Res 56:1493-1497.
6. Glockner S, Lehmann U, Wilke N, Kleeberger W, Langer F, and Kreipe H (2000). Detection of gene amplification in intraductal and infiltrating breast cancer by laser-assisted microdissection and quantitative real-time PCR. Pathobiology 68:173-179.
7. Glockner S, Lehmann U, Wilke N, Kleeberger W, Langer F, and Kreipe H (2001). Amplification of growth regulatory genes in intraductal breast cancer is associated with higher nuclear grade but not with the progression to invasiveness. Lab Invest 81:565-571.
8. Jarvinen TA, Tanner M, Barlund M, Borg A, and Isola J (1999). Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosom Cancer 26:142-150.
9. Jarvinen TA, Tanner M, Rantanen V, Barlund M, Borg A, Grenman S, and Isola J (2000). Amplification and deletion of topoisomerase Ilalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 156:839-847.
10. Kallioniemi OP, Kallioniemi A, Kurisu W, Thor A, Chen LC, Smith HS, Waldman FM, Pinkel D, and Gray JW (1992). ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA 89:5321-5325.
11. Kuukasjarvi T, Karhu R, Tanner M, Kahkonen M, Schaffer A, Nupponen N, Pennanen S, Kallioniemi A, Kallioniemi OP, and Isola J (1997). Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res 57:1597-1604.
12. Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM, and Hynes NE (2000). ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: Receptor overexpression does not determine growth dependency. Mol Cell Biol 20:3210-3223.
13. Lehmann U, Glockner S, Kleeberger W, Feist H, von Wasielewski R, and Kreipe H (2000). Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction. Am J Pathol 156:1855-1864.
14. Liao DJ and Dickson RB (2000). c-Myc in breast cancer. Endocr Relat Cancer 7:143-164.
15. Lonn U, Lonn S, Nilsson B, and Stenkvist B (1994). Intratumoral heterogeneity for amplified genes in human breast carcinoma. Int J Cancer 58:40-45.
16. Mai S (1994). Overexpression of c-myc precedes amplification of the gene encoding dihydrofolate reductase. Gene 148:253-260.
17. Mai S, Fluri M, Siwarski D, and Huppi K (1996). Genomic instability in MycER-activated Rat1A-MycER cells. Chromosome Res 4:365-371.
18. Menard S, Casalini P, Campiglio M, Pupa S, Agresti R, and Tagliabue E (2001). HER2 overexpression in various tumor types, focusing on its relationship to the development of invasive breast cancer. Ann Oncol 12:S15-S19.
19. Pertschuk LP, Axiotis CA, Feldman JG, Kim YD, Karavattayhayyil SJ, and Braithwaite L (1999). Marked intratumoral heterogeneity of the proto-oncogene Her-2/neu determined by three different detection systems. Breast J 5:369-374.
20. Shen CY, Yu JC, Lo YL, Kuo CH, Yue CT, Jou YS, Huang CS, Lung JC, and Wu CW (2000). Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: An implication for mutator phenotype and breast cancer pathogenesis. Cancer Res 60:3884-3892.
21. Slamon DJ, Press MF, and Godolphin W (1989). Studies of the Her-2/neu proto-oncogene in human breast cancer. Cancer Cells 1:371-384.
22. Smith K, Houlbrook S, Greenall M, Carmichael J, and Harris AL (1993). Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: Relationship to m-AMSA and mitoxantrone sensitivity. Oncogene 8:933-938.
23. Szollosi J, Balazs M, Feuerstein BG, Benz CC, and Waldman FM (1995). ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. Cancer Res 55:5400-5407.
24. Thor A (2001). HER2: A discussion of testing approaches in the USA. Ann Oncol 12:S101-S107.